Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn's Disease: A Prospective Pilot Study.

Lorenzo BertaniLuca AntonioliMarco ForniliVanessa D'AntongiovanniLinda CeccarelliLuca CarmiscianoLaura BenvenutiMaria Gloria MumoloAndrea BottariVeronica PardiGiovanni Baiano SvizzeroLaura BagliettoNicola De BortoliMassimo BelliniMatteo FornaiFrancesco Costa

Published in: Inflammatory bowel diseases (2024)

This pilot study showed that IL-23 and FC could be reliable biomarkers in predicting therapeutic outcome to UST therapy in CD. In particular, the correlation between baseline serum levels of IL-23 and mucosal healing at 48 weeks is particularly strong, paving the way for its use to drive therapeutic decisions.

Keyphrases

stem cells
bone marrow
replacement therapy